临床试验登记· The First Affiliated Hospital of Bengbu Medical University · ClinicalTrials.gov·· 10 小时前评分30
Becotatug Vedotin（MRG003）联合免疫治疗及多模式放疗用于二线及以后晚期 ESCC
Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting
导读
蚌埠医科大学第一附属医院登记一项评估 Becotatug vedotin 联合免疫治疗及多模式放疗治疗二线及以后晚期 ESCC 的临床试验。NCT07892833为2期单臂、单中心探索性研究，拟入组38人并正在招募；Becotatug vedotin（MRG003）2.0 mg/kg，每21天静脉给药一次。
来源：临床试验登记 · clinicaltrials.gov